** Proteus®PLUS is the brand name of a configuration of the Proteus® 235.
*** Proteus®ONE is the brand name of a configuration of the Proteus® 235.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Notes to Editors
About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.
Today, more than half of proton therapy clinical facilities worldwide use IBA systems. This includes 17 proton therapy centers in operation and 12 centers under development. Over 25,000 patients have been treated with IBA equipment - more than all competitor installations combined.
About IBA
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.
Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.
IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
For further information please contact:
IBA
Jean-Marc Bothy
Chief Financial Officer
t. +32 10 475 890
e. Investorrelations@iba-group.com
For media and investor enquiries
Consilium Strategic Communications
Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Jessica Hodgson, Ivar Milligan
t. +44 (0) 20 3709 5700
